MCID: HMP009
MIFTS: 49

Haemophilus Influenzae

Categories: Rare diseases, Infectious diseases

Aliases & Classifications for Haemophilus Influenzae

Summaries for Haemophilus Influenzae

MalaCards based summary : Haemophilus Influenzae, also known as h. influenzae, is related to septic arthritis and endocarditis. An important gene associated with Haemophilus Influenzae is OMP (Olfactory Marker Protein), and among its related pathways/superpathways are Innate Immune System and Toll-Like receptor Signaling Pathways. The drugs Amoxicillin and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and colon, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 72 Haemophilus influenzae (formerly called Pfeiffer\'s bacillus or Bacillus influenzae) is a Gram-negative,... more...

Related Diseases for Haemophilus Influenzae

Diseases related to Haemophilus Influenzae via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 287)
# Related Disease Score Top Affiliating Genes
1 septic arthritis 30.6 CXCL8 TLR2
2 endocarditis 30.1 CXCL8 TLR2 TNF
3 otitis media 30.0 CXCL8 IL1B TLR2 TNF
4 tonsillitis 29.9 CXCL8 IL1B TNF
5 meningitis 29.8 CXCL8 IL1B OMP TLR2 TNF
6 pharyngitis 29.7 CXCL8 IL1B
7 pneumonia 29.7 CXCL8 IL1B TLR2 TNF VTN
8 lung disease 29.6 CXCL8 IL1B TNF
9 bacterial meningitis 29.4 CXCL8 IL1B TLR2 TNF
10 endometritis 29.4 IL1B TNF
11 aseptic meningitis 29.3 CXCL8 IL1B TNF
12 prostatitis 29.3 CXCL8 IL1B TNF
13 pyelonephritis 29.3 CXCL8 IL1B TNF
14 chorioamnionitis 29.3 CXCL8 IL1B TNF
15 duodenal ulcer 29.3 CXCL8 IL1B TNF
16 osteomyelitis 29.3 CXCL8 IL1B TNF
17 peritonitis 29.2 CXCL8 IL1B TLR2 TNF
18 haemophilus meningitis 11.7
19 epiglottitis 11.5
20 complement component 3 deficiency, autosomal recessive 11.1
21 specific antibody deficiency 11.1
22 influenza 11.1
23 bronchitis 10.8
24 tetanus 10.7
25 pertussis 10.6
26 diphtheria 10.6
27 hepatitis 10.5
28 hepatitis b 10.5
29 aging 10.4
30 mycobacterium chelonae 10.4 CXCL8 TLR2
31 mycobacterium kansasii 10.4 CXCL8 TLR2
32 tungiasis 10.4 CXCL8 TNF
33 streptococcal toxic-shock syndrome 10.4 CXCL8 TNF
34 trichuriasis 10.3 CXCL8 TNF
35 clonorchiasis 10.3 CXCL8 TNF
36 pouchitis 10.3 CXCL8 LTF
37 melancholia 10.3 TF TNF
38 meconium aspiration syndrome 10.3 CXCL8 TNF
39 felty syndrome 10.3 CXCL8 LTF
40 giant papillary conjunctivitis 10.3 CXCL8 LTF
41 neisseria meningitidis infection 10.3 OMP TLR2
42 trench fever 10.3 TLR2 TNF
43 superficial siderosis of the central nervous system 10.3 LTF TF
44 sebaceous gland disease 10.3 CXCL8 TLR2
45 superficial siderosis 10.3 LTF TF
46 louse-borne relapsing fever 10.3 CXCL8 TNF
47 transverse myelitis 10.3 CXCL8 TNF
48 penicilliosis 10.3 TLR2 TNF
49 poliomyelitis 10.3
50 nontuberculous mycobacterial lung disease 10.3 TLR2 TNF

Graphical network of the top 20 diseases related to Haemophilus Influenzae:



Diseases related to Haemophilus Influenzae

Symptoms & Phenotypes for Haemophilus Influenzae

MGI Mouse Phenotypes related to Haemophilus Influenzae:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.56 TF TLR2 TNF VTN CFH CLEC7A
2 homeostasis/metabolism MP:0005376 9.28 OMP TF TLR2 TNF VTN CFH

Drugs & Therapeutics for Haemophilus Influenzae

Drugs for Haemophilus Influenzae (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 140)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 26787-78-0 33613 2171
2
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
3
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
4
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
5
Ibuprofen Approved Phase 4 15687-27-1 3672
6
Azithromycin Approved Phase 4 83905-01-5 53477736 447043 55185
7
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
8
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
9
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
10
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 60-00-4, 62-33-9 6049
11 Strawberry Approved, Nutraceutical Phase 4,Phase 3
12 Clavulanic Acid Phase 4,Phase 3,Phase 2
13 Fluoroquinolones Phase 4,Phase 3
14 Amoxicillin-Potassium Clavulanate Combination Phase 4,Phase 3,Phase 2
15 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
16 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2,Phase 1
17 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3
19 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2
20 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
21 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
22 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
23 beta-Lactamase Inhibitors Phase 4,Phase 3,Phase 2
24 Estradiol valerate Phase 4 979-32-8
25 Analgesics Phase 4,Phase 3,Phase 1
26 MF59 oil emulsion Phase 4
27 Chelating Agents Phase 4,Phase 3,Phase 2
28 Tetanus Antitoxin Phase 4,Phase 3
29 Contraceptive Agents Phase 4
30 Contraceptives, Oral Phase 4
31 Contraceptives, Oral, Combined Phase 4
32 Cyclooxygenase Inhibitors Phase 4
33 Analgesics, Non-Narcotic Phase 4,Phase 3
34 Norgestimate, ethinyl estradiol drug combination Phase 4
35 Ophthalmic Solutions Phase 4
36 Diphtheria Antitoxin Phase 4,Phase 3
37 Pentetic Acid Phase 4,Phase 3,Phase 2
38 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1
39 Anticoagulants Phase 4,Phase 3,Phase 2
40 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
41 Estradiol 17 beta-cypionate Phase 4
42 Estradiol 3-benzoate Phase 4
43 Antidotes Phase 4,Phase 3,Phase 2
44 Polyestradiol phosphate Phase 4
45 Anti-Inflammatory Agents Phase 4
46 Anti-Inflammatory Agents, Non-Steroidal Phase 4
47 Protective Agents Phase 4,Phase 3,Phase 2
48 Iron Chelating Agents Phase 4,Phase 3,Phase 2
49 Antipyretics Phase 4,Phase 3
50 Antirheumatic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 292)

# Name Status NCT ID Phase Drugs
1 Middle Meatal Bacteriology During Acute Respiratory Infection in Children Unknown status NCT00545961 Phase 4 placebo;amoxicillin clavulanate acid
2 Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine Unknown status NCT00877357 Phase 4
3 Safety of Haemophilus Influenza Type b Vaccine When Administered to Korean Children Completed NCT01404962 Phase 4
4 The Safety and Immunogenicity of Haemophilus Influenzae Type b Vaccine in Different Injection Site Completed NCT01761136 Phase 4
5 Assess Safety & Reactogenicity of GSK Biologicals' Hib Vaccine Co-administered With or Without Chinese DTPw Vaccine Completed NCT00158795 Phase 4
6 Study to Eliminate Hib Carriage in Rural Alaska Native Villages Completed NCT00153556 Phase 4
7 The Immediate and Longterm Immune Responses of UK Infants and Young Children to a Booster Dose of Hib Vaccine Completed NCT00197782 Phase 4
8 Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine Completed NCT00454987 Phase 4
9 Hepatitis B Vaccination in Infants Completed NCT01896596 Phase 4
10 Immunogenicity of the Booster Dose of Two MenC Vaccines Completed NCT00392808 Phase 4
11 Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years Completed NCT02215863 Phase 4
12 Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox Completed NCT00668304 Phase 4 Avelox (Moxifloxacin, BAY12-8039)
13 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora Completed NCT00312338 Phase 4 VIGAMOX
14 Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine Completed NCT00674908 Phase 4
15 Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine Completed NCT00617812 Phase 4
16 Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068) Completed NCT00289913 Phase 4
17 Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants Completed NCT00325156 Phase 4
18 Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Completed NCT00254917 Phase 4
19 Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ Completed NCT01358825 Phase 4
20 Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course Completed NCT01457547 Phase 4
21 Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Completed NCT00753649 Phase 4
22 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Completed NCT01659996 Phase 4
23 Retrospective Survey of Safety of Fourth Dose Pentacel® in Children Completed NCT00772369 Phase 4
24 Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ Completed NCT00802867 Phase 4
25 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
26 Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China Completed NCT01491087 Phase 4
27 Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13® Completed NCT01392378 Phase 4 Paracetamol;Ibuprofen;Paracetamol;Ibuprofen
28 Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination Completed NCT01357720 Phase 4
29 Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency Completed NCT00520494 Phase 4 Vivaglobin
30 Tripartite International Research for the Elimination of Trachoma Completed NCT01202331 Phase 4 mass treatment with oral azithromycin
31 Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Recruiting NCT02422264 Phase 4 Prevnar13
32 Vaccinating Children After Chemotherapy Recruiting NCT02447718 Phase 4
33 Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Recruiting NCT02853929 Phase 4
34 Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B Active, not recruiting NCT03125616 Phase 4
35 Study Comparing DTP-HB-Hib by Disposable-Syringe Jet Injector To Vaccination By Needle And Syringe In Infants Terminated NCT02409095 Phase 4
36 Safety and Immunogenicity of Haemophilus Influenzae Type b Conjugate Vaccine,Freeze-dried Unknown status NCT02560272 Phase 3
37 Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children Unknown status NCT01619462 Phase 3
38 Randomized Study on Efficacy of Gemifloxacin-based Regimen for Helicobacter Pylori Infection Unknown status NCT02368470 Phase 3 Gemifloxacin-based triple therapy;Standard triple therapy
39 Study in Toddlers (12-18 Months) Comparing a Booster Dose of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b Infections in China Completed NCT01025544 Phase 3
40 Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b Completed NCT00808392 Phase 3
41 Study in Infants (6-12 Months) Comparing Two Doses of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Vaccine Versus a Tetanus Toxoid-Conjugated Vaccine Available for the Prevention of Haemophilus Influenzae Type b Infections in China Completed NCT01044316 Phase 3
42 A Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine Completed NCT02692859 Phase 3
43 Immunogenicity and Safety of a Booster Dose of Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 365-569 Days Old Healthy Infants Completed NCT01226953 Phase 3
44 Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese Children Completed NCT02139228 Phase 3
45 Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED) Completed NCT00441012 Phase 3
46 Immunogenicity and Safety of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children Completed NCT01125527 Phase 3
47 Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B Completed NCT01362517 Phase 3
48 Immunogenicity and Safety Study of LBVH0101 in Healthy Infants at Two, Four and Six Months of Age Completed NCT01019772 Phase 3
49 Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age Completed NCT00345579 Phase 3
50 Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED) Completed NCT00092469 Phase 3

Search NIH Clinical Center for Haemophilus Influenzae

Genetic Tests for Haemophilus Influenzae

Anatomical Context for Haemophilus Influenzae

MalaCards organs/tissues related to Haemophilus Influenzae:

38
Testes, Lung, Colon, B Cells, Tonsil, Monocytes, Neutrophil

Publications for Haemophilus Influenzae

Articles related to Haemophilus Influenzae:

(show top 50) (show all 613)
# Title Authors Year
1
GyrA and/or ParC alterations of Haemophilus influenzae strains isolated from the urethra of men with acute urethritis. ( 29138021 )
2018
2
Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity. ( 29336924 )
2018
3
The adhesins of non-typeable Haemophilus influenzae. ( 29415569 )
2018
4
Haemophilus influenzae-protein D specific antibody correlate with protection against acute otitis media in young children. ( 29395516 )
2018
5
Changing Epidemiology of Haemophilus influenzae in Children. ( 29233576 )
2018
6
Mutant selection window of four quinolone antibiotics against clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. ( 29290527 )
2018
7
Antimicrobial activity of a novel bioengineered honey against non-typeable<i>Haemophilus influenzae</i>biofilms: an in vitro study. ( 29449345 )
2018
8
Single nucleotide polymorphisms in genes encoding penicillin-binding proteins in I^-lactamase-negative ampicillin-resistant Haemophilus influenzae in Japan. ( 29352811 )
2018
9
Nontypeable Haemophilus influenzae DNA stimulates type I interferon expression via STING signaling pathway. ( 29421524 )
2018
10
Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III randomized study. ( 29277353 )
2018
11
Antibacterial activity of Artemisia asiatica essential oil against some common respiratory infection causing bacterial strains and its mechanism of action in Haemophilus influenzae. ( 29241769 )
2018
12
Pneumococcal phenotype and interaction with nontypeable<i>Haemophilus influenzae</i>as determinants of otitis media progression. ( 29378791 )
2018
13
Molecular diagnosis and characterization of a culture-negative mycotic aneurysm due to ST54 Haemophilus influenzae type b with PBP 3 alterations. ( 29373266 )
2018
14
Cephalosporin-3'-Diazeniumdiolate NO Donor Prodrug PYRRO-C3D Enhances Azithromycin Susceptibility of Nontypeable Haemophilus influenzae Biofilms. ( 27919896 )
2017
15
Rapid and Accurate Diagnosis of Acute Pyogenic Meningitis Due to<i>Streptococcus Pneumoniae</i>,<i>Haemophilus influenzae</i>Type b and<i>Neisseria meningitidis</i>Using A Multiplex PCR Assay. ( 29207725 )
2017
16
The DNABII family of proteins is comprised of the only nucleoid associated proteins required for nontypeable Haemophilus influenzae biofilm structure. ( 29230970 )
2017
17
Antimicrobial activity of antisense peptide-peptide nucleic acid conjugates against non-typeable Haemophilus influenzae in planktonic and biofilm forms. ( 27986898 )
2017
18
Paediatric invasive Haemophilus influenzae in Queensland, Australia, 2002-2011: Young Indigenous children remain at highest risk. ( 28871608 )
2017
19
Investigating the candidacy of a capsular polysaccharide-based glycoconjugate as a vaccine to combat Haemophilus influenzae type a disease: A solution for an unmet public health need. ( 28951087 )
2017
20
Experimental design and metabolic flux analysis tools to optimize industrially relevant Haemophilus influenzae type b growth medium. ( 28840658 )
2017
21
Alloiococcus otitidis Forms Multispecies Biofilm with Haemophilus influenzae: Effects on Antibiotic Susceptibility and Growth in Adverse Conditions. ( 28824879 )
2017
22
Haemophilus influenzae serotype f endocarditis and septic arthritis. ( 28725560 )
2017
23
Structural analyses of the Haemophilus influenzae peptidoglycan synthase activator LpoA suggest multiple conformations in solution. ( 28887305 )
2017
24
First Necrotizing Fasciitis Caused by<i>Haemophilus influenza</i>Serotype a. ( 29124073 )
2017
25
Pneumonia prevention: Cost-effectiveness analyses of two vaccines among refugee children aged under two years, Haemophilus influenzae type b-containing and pneumococcal conjugate vaccines, during a humanitarian emergency, Yida camp, South Sudan. ( 27989625 )
2017
26
Haemophilus influenzae biofilms in primary ciliary dyskinesia: a moving story. ( 28890441 )
2017
27
Haemophilus influenzae Type b Invasive Disease in Amish Children, Missouri, USA, 2014. ( 27983486 )
2017
28
Development of a highly resolved loop-mediated isothermal amplification method to detect the N526K ftsI mutation of I^-lactamase-negative ampicillin-resistant Haemophilus influenzae. ( 28807759 )
2017
29
Immunogenicity, safety and reactogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in 2-17-year-old children with asplenia or splenic dysfunction: A phase 3 study. ( 28866290 )
2017
30
Haemophilus influenzae Isolated From Men With Acute Urethritis: Its Pathogenic Roles, Responses to Antimicrobial Chemotherapies, and Antimicrobial Susceptibilities. ( 28282645 )
2017
31
Decreased AOM with Treatment Failure Following Introduction of the Ten-Valent Pneumococcal Haemophilus influenzae Protein D Conjugate Vaccine. ( 29278616 )
2017
32
Extracellular DNA and Type IV Pilus Expression Regulate the Structure and Kinetics of Biofilm Formation by Nontypeable<i>Haemophilus influenzae</i>. ( 29259083 )
2017
33
Budget impact analysis of vaccination against Haemophilus influenzae type b as a part of a Pentavalent vaccine in the childhood immunization schedule of Iran. ( 28088246 )
2017
34
Economic Evaluation and Budget Impact Analysis of Vaccination against<i>Haemophilus influenzae</i>Type b Infection in Thailand. ( 29209602 )
2017
35
Haemophilus influenzae Pyomyositis in a Patient with Diabetic Ketoacidosis: A Unique Case and Review of Literature. ( 28352482 )
2017
36
Fulminant Haemophilus influenzae Type A Infection in a 4-year-Old with Previously Undiagnosed Asplenic Heterotaxy. ( 28858039 )
2017
37
Optimization of Haemophilus influenzae adhesin transmembrane domain expression in Escherichia coli. ( 29284141 )
2017
38
Vaccine Candidates against Nontypeable Haemophilus influenzae: a Review ( 28088130 )
2017
39
Beta-lactam resistance among Haemophilus influenzae isolates in Poland. ( 28818575 )
2017
40
Transcriptional Modulation of Penicillin-Binding Protein 1b, Outer Membrane Protein P2 and Efflux Pump (AcrAB-TolC) during Heat Stress Is Correlated to Enhanced Bactericidal Action of Imipenem on Non-typeable<i>Haemophilus influenzae</i>. ( 29375536 )
2017
41
Haemophilus influenzae type b (Hib) seroprevalence and current epidemiology in England and Wales. ( 29289561 )
2017
42
Hib antibody responses in infants following diphtheria, tetanus, acellular pertussis, and conjugated Haemophilus influenzae type b (Hib) combination vaccines with decreasing amounts of tetanus toxoid. ( 29054729 )
2017
43
Immunogenicity of Nontypeable Haemophilus influenzae Outer Membrane Vesicles and Protective Ability in the Chinchilla Model of Otitis Media. ( 28768669 )
2017
44
Blood-Brain Barrier in a Haemophilus influenzae Type a In Vitro Infection: Role of Adenosine Receptors A2A and A2B. ( 28921456 )
2017
45
Nontypeable Haemophilus influenzae (NTHi) directly interfere with the regulation of E-cadherin in lung epithelial cells. ( 28802586 )
2017
46
Haemophilus influenzae Serotype f Epiglottitis: A Case Report and Review. ( 28028010 )
2017
47
Conservation and Recombination in the Genome Sequence of Haemophilus influenzae Type f WAPHL1. ( 28935730 )
2017
48
Amino acid substitution in the major multi-drug efflux transporter protein AcrB contributes to azithromycin low-susceptibility in Haemophilus influenzae. ( 28848006 )
2017
49
Epidemiology of invasive pneumococcal and haemophilus influenzae diseases in northwestern ontario, canada (2010-2015). ( 28951105 )
2017
50
Antimicrobial susceptibility of Haemophilus influenzae strains isolated from the urethra of men with acute urethritis and/or epididymitis. ( 28619239 )
2017

Variations for Haemophilus Influenzae

Expression for Haemophilus Influenzae

Search GEO for disease gene expression data for Haemophilus Influenzae.

Pathways for Haemophilus Influenzae

Pathways related to Haemophilus Influenzae according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 CFH CLEC7A CXCL8 IL1B LTF TLR2
2
Show member pathways
12.76 CLEC7A CXCL8 IL1B TLR2 TNF
3
Show member pathways
12.63 CXCL8 IL1B TLR2 TNF
4
Show member pathways
12.46 IL1B TLR2 TNF VTN
5
Show member pathways
12.35 CXCL8 IL1B TLR2 TNF
6 12.16 TLR2 TNF VTN
7
Show member pathways
12.12 CXCL8 TLR2 TNF
8
Show member pathways
12.12 CXCL8 IL1B TNF
9
Show member pathways
12.11 IL1B TLR2 TNF
10
Show member pathways
12.11 CXCL8 IL1B TLR2 TNF
11
Show member pathways
12 CXCL8 IL1B TNF
12 11.96 CLEC7A IL1B TLR2 TNF
13
Show member pathways
11.89 CXCL8 IL1B TLR2 TNF
14 11.86 CXCL8 IL1B TNF
15 11.83 CXCL8 IL1B TNF
16 11.83 CXCL8 IL1B TF TNF
17 11.79 CXCL8 IL1B VTN
18
Show member pathways
11.78 IL1B TLR2 TNF
19 11.75 CXCL8 IL1B TNF
20 11.72 CXCL8 IL1B TNF
21 11.65 CLEC7A TLR2 VTN
22 11.58 CXCL8 IL1B TNF
23 11.54 CXCL8 IL1B TLR2 TNF
24 11.49 CXCL8 IL1B TNF
25
Show member pathways
11.47 CXCL8 IL1B TNF
26 11.41 CXCL8 IL1B TLR2 TNF
27 11.32 CXCL8 IL1B TNF
28 11.29 IL1B TLR2 TNF
29 11.23 IL1B TNF
30 11.23 IL1B TNF
31 11.18 IL1B TNF
32 11.17 IL1B TNF
33 11.15 IL1B TNF
34 11.07 CXCL8 IL1B TNF
35 11.05 IL1B TLR2
36 11.03 CXCL8 TNF
37 11 CXCL8 IL1B TLR2 TNF
38 10.98 IL1B TNF
39 10.91 CXCL8 TNF
40 10.83 IL1B TNF
41 10.61 CXCL8 IL1B TLR2 TNF

GO Terms for Haemophilus Influenzae

Cellular components related to Haemophilus Influenzae according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.56 LTF TF TLR2 TNF
2 extracellular region GO:0005576 9.5 CFH CXCL8 IL1B LTF TF TNF
3 blood microparticle GO:0072562 9.33 CFH TF VTN
4 extracellular space GO:0005615 9.17 CFH CXCL8 IL1B LTF TF TNF

Biological processes related to Haemophilus Influenzae according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.8 CXCL8 IL1B TLR2 TNF VTN
2 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.78 IL1B LTF TNF
3 inflammatory response GO:0006954 9.65 CLEC7A CXCL8 IL1B TLR2 TNF
4 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.62 IL1B TNF
5 positive regulation of phagocytosis GO:0050766 9.61 IL1B TNF
6 positive regulation of interleukin-6 production GO:0032755 9.61 IL1B TLR2 TNF
7 positive regulation of receptor-mediated endocytosis GO:0048260 9.6 TF VTN
8 positive regulation of chemokine production GO:0032722 9.59 TLR2 TNF
9 embryonic digestive tract development GO:0048566 9.58 CXCL8 TNF
10 negative regulation of lipid catabolic process GO:0050995 9.58 IL1B TNF
11 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.57 IL1B TNF
12 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.56 IL1B VTN
13 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.55 IL1B TNF
14 response to molecule of bacterial origin GO:0002237 9.54 CXCL8 TLR2
15 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.52 IL1B TNF
16 positive regulation of chemokine biosynthetic process GO:0045080 9.51 IL1B TNF
17 lipopolysaccharide-mediated signaling pathway GO:0031663 9.5 IL1B TLR2 TNF
18 regulation of establishment of endothelial barrier GO:1903140 9.49 IL1B TNF
19 positive regulation of fever generation GO:0031622 9.48 IL1B TNF
20 sequestering of triglyceride GO:0030730 9.46 IL1B TNF
21 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.46 IL1B LTF TLR2 TNF
22 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.37 IL1B TNF
23 positive regulation of interleukin-8 production GO:0032757 9.13 IL1B TLR2 TNF
24 positive regulation of NF-kappaB import into nucleus GO:0042346 8.8 IL1B TLR2 TNF

Molecular functions related to Haemophilus Influenzae according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.43 CXCL8 IL1B TNF
2 lipopolysaccharide binding GO:0001530 9.16 LTF TLR2
3 heparin binding GO:0008201 9.13 CFH LTF VTN
4 signaling pattern recognition receptor activity GO:0008329 8.62 CLEC7A TLR2

Sources for Haemophilus Influenzae

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....